Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12786615 | 0.75 | MAPT (0.48) | ACHEABCG2HCAR2CYP3A4ALDH1A1 | |
| SCHEMBL18470455 | 0.72 | KMT2A (1.00) | KMT2AACHECYP3A4ALDH1A1LMNA | |
| SCHEMBL3256443 | 0.71 | CYP3A4 (0.39) | ACHEABCG2HCAR2CYP3A4ALDH1A1 | |
| SCHEMBL2800678 | 0.71 | IDO1 (0.41) | KMT2AACHEABCG2HCAR2CYP3A4 | |
| SCHEMBL2760674 | 0.71 | GPR3 (0.52) | ACHEABCG2HCAR2CYP3A4ALDH1A1 | |
| SCHEMBL1008832 | 0.71 | DHFR (0.46) | KMT2AACHEABCG2HCAR2CYP3A4 | |
| SCHEMBL10064618 | 0.68 | KMT2A (0.58) | KMT2ACYP3A4ALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL639710 | 0.68 | KMT2A (0.53) | KMT2ACYP3A4ALDH1A1LMNAKDM4E | |
| SCHEMBL2646977 | 0.67 | PLAU (0.50) | KMT2AACHECYP3A4ALDH1A1LMNA | |
| SCHEMBL14629305 | 0.67 | KDM4E (0.44) | KMT2AACHEABCG2HCAR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228375-A1 | New xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1562946-B1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-7696212-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090093457-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | disclosed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | disclosed |
| EP-1562946-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004041820-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | KMT2A 3970/4885ACHE 469/4885ABCG2 57/4885 |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | KMT2A 3711/4885ACHE 309/4885ABCG2 34/4885 |
| US-20090093457-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | KMT2A 3711/4885ACHE 309/4885ABCG2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.